Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE

BACKGROUND: Monitoring of pancreatic neuroendocrine tumors (PanNET) undergoing peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE depends on changes in tumor size, which often occur late. Tumor growth rate (TGR) allows for quantitative assessment of the tumor kinetics expressed as %/...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Endocr Connect
Asıl Yazarlar: Pettersson, Olof Joakim, Fröss-Baron, Katarzyna, Crona, Joakim, Sundin, Anders
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Bioscientifica Ltd 2021
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111309/
https://ncbi.nlm.nih.gov/pubmed/33875614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-21-0027
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller